PubMed COVID-19 Clinical Care

Objective Disease-modifying treatments (DMT) in multiple sclerosis (M.S.) may affect the course and outcome of COVID-19, but withholding them could permit disease activity. This paper aims to understand the course of COVID-19 in patients with MS

CONCLUSIONS: In patients with acute respiratory failure due to COVID-19, survival did not change between first, second, and third waves while the use of invasive MV decreased. HFNO or intravenous steroids were not associated with better outcomes

Introduction Obesity and aging negatively affect the immune system and host defense mechanisms, increasing vulnerability to, worsening prognosis of infectious diseases and leading to vaccine failure. Our aim is to investigate the antibody response

Since the global outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a symptom of the onset of SARS-CoV-2, olfactory dysfunction (OD), has attracted tremendous attention. OD is not only a negative factor for quality of life but

CONCLUSION: Our findings imply that the presence of minor myocardial scars has limited clinical significance with respect to cardiopulmonary function after COVID-19. .

No abstract

CONCLUSION: Using a diagnostic questionnaire increased clinicians' ability to come to a diagnosis in telephone consultations.

CONCLUSION: HCQ can reduce the mature hERG channel expression and IhERG via enhancing channel degradation. The QT prolongation effect of HCQ is mediated by typical hERG binding sites involving residues Tyr652 and Phe656.

N/A.

CONCLUSION: The MCO membrane was more effective in removing IL-6 and was better tolerated than the LF membrane. Large, randomized controlled trials are required to confirm the relative benefits of the MCO membrane, especially mortality. However, due